$ cat ./records/collaborated-with-chinese-health-institutions-on-open-covid-19-dr-2020.txt
Collaborated with Chinese health institutions on open COVID-19 drug-discovery data platform
[RECORD.TXT] · cat --full
Within days of the novel coronavirus being identified, GHDDI — co-funded by the Gates Foundation and Tsinghua University — launched an open COVID-19 data platform aggregating known drug candidates, computational models, and research targets to accelerate global therapeutic discovery. The platform was made freely available to researchers worldwide and became one of the earliest open-science responses to the pandemic. The rapid mobilization demonstrated the practical value of the Foundation's decade-long investment in Chinese drug discovery infrastructure.
Free forever · No ads · Solo developer
If this was worth a read, help make the next entry possible.
Every entry in this archive was researched, verified, and written by one person — for free. No corporate funding. No ad revenue. Just a developer who believes verified history should be accessible to everyone. Your donation directly funds new entries.
Crypto accepted · No subscription required
← Previous
Directed nearly $6 billion in agriculture grants to Africa over 17 years — the largest private agricultural aid commitment in history
Next →
Backs Pivot Bio's nitrogen-fixing microbes as a climate-friendly alternative to synthetic fertilizer
[CROSS_REFERENCES] · grep --category='Global Health'
Related Accomplishments
January 2026
Gates-backed World Mosquito Program reaches 16 million people protected from dengue via Wolbachia method
The World Mosquito Program — backed in part by the Gates Foundation — announced in January 2026 that its Wolbachia-infected mosquito releases had reached over 16.1 million people across multiple countries, including Colombia, Indonesia, Brazil, Sri Lanka, Fiji, Vanuatu, and Vietnam. Wolbachia-carrying Aedes aegypti mosquitoes — which block dengue, Zika, chikungunya, and yellow fever transmission — had established self-sustaining populations in treated cities without requiring ongoing releases. Gold-standard randomised trials in Indonesia showed a 77% reduction in dengue incidence. The program represented one of the largest and most cost-effective vector control deployments in history.
2025
Gates-Funded Monoclonal Antibody Shows Early Promise as a Single-Shot Malaria Shield
[ARCHIVE_FUNDING] · INDEPENDENT · NO ADS
One developer. >300 verified entries. Zero ads. Forever free.
No sponsors, no paywall, no algorithm. If this archive has been useful to you, reader support is what keeps it running.